SCHEMBL1503897

SCHEMBL1503897

CCOC(=O)C1=Cc2ccc(Cl)cc2OC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
ALOX5 P09917 2/20 0.46
HTT P42858 3/20 0.46
USP2 O75604 1/20 0.46
CCR2 P41597 1/20 0.45
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
MAPT P10636 5/20 0.44
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 2/20 0.44
NFKB1 P19838 2/20 0.44
RAB9A P51151 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.42
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385872 0.87 CA12 (0.47) CA12CA9HTTUSP2CCR2
SCHEMBL13394278 0.85 ALOX5 (0.47) CA12CA9ALOX5HTTKMT2A
SCHEMBL22071065 0.84 ALOX5 (0.46) ALOX5HTTCCR2KMT2AMAPT
SCHEMBL22070643 0.82 ALOX5 (0.44) ALOX5HTTKMT2AMAPTKDM4E
SCHEMBL4537381 0.81 ALDH1A1 (0.61) ALOX5HTTKMT2AMEN1MAPT
SCHEMBL29435098 0.81 ALDH1A1 (0.61) ALOX5HTTKMT2AMEN1MAPT
SCHEMBL29495392 0.79 MEN1 (0.51) CA12CA9ALOX5HTTCCR2
SCHEMBL1504097 0.79 MEN1 (0.51) CA12CA9ALOX5HTTCCR2
SCHEMBL10650749 0.77 ALDH1A1 (0.50) CA12CA9ALOX5HTTKMT2A
SCHEMBL7380758 0.77 CA12 (0.47) CA12CA9HTTUSP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 CA12 3135/4885CA9 3491/4885ALOX5 684/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R CA12 3961/4885CA9 4288/4885ALOX5 899/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R CA12 3961/4885CA9 4288/4885ALOX5 899/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R CA12 3961/4885CA9 4288/4885ALOX5 899/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R CA12 3961/4885CA9 4288/4885ALOX5 899/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 CA12 1305/4885CA9 1232/4885ALOX5 2973/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R CA12 3968/4885CA9 4362/4885ALOX5 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.